The Effect of Simvastatin Therapy on the Expression of Procoagulant and Inflammatory Markers in Heart Failure
This study has been completed.
First Posted: October 9, 2008
Last Update Posted: March 31, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Information provided by (Responsible Party):
mark munger, University of Utah
Our proposed research will examine whether treatment with simvastatin alters expression and activity of monocyte TF, whether polymorphisms in the TF gene alter the therapeutic effect and what effect treatment has on inflammatory markers in heart failure. The results of this study may assist in tailoring statin therapy to specific characteristics, such as inflammatory state, of heart failure patients. If treatment with simvastatin significantly lowers TF expression, this may reduce the risk of thromboembolic events in patients with heart failure, thus reducing mortality and morbidity. If the treatment effect varies based on the TF genotype, this may define an identifiable population in whom statin therapy may be more beneficial than the population as a whole.
Early Phase 1
||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
||The Effect of Simvastatin Therapy on the Expression of Procoagulant and Inflammatory Markers in Heart Failure
Primary Outcome Measures:
- Measure the effect of simvastatin treatment on the expression and activity of TF in patients with heart failure. [ Time Frame: May 2005-June 2008 ]
Secondary Outcome Measures:
- Determine if polymorphisms in the gene coding for TF affect the impact of simvastatin therapy on tissue factor expression [ Time Frame: May 2005-June 2008 ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||July 2008 (Final data collection date for primary outcome measure)
Simvastatin 40 mg tablet
Other Name: Zocor